Clinical Characteristics and Severity of COVID-19 at COVID-19 Referral Hospital in Bogor, West Java, Indonesia (original) (raw)

Introduction: Although many studies were published during the COVID-19 pandemic's early stages, we still do not know much about the severity of COVID-19 in terms of clinical evidence about signs and symptoms and specific clinical characteristics. When exposed, even asymptomatic (OTG) patients have a terrible prognosis. This study aimed to examine the connection between clinical features and COVID-19 poverty during the 2020 pandemic at the Covid-19 referral hospital in Bogor City, Indonesia. Methods: The research is cross-sectional. Data extended from the National Institute of Health Research and Development's ongoing research into comorbidities and COVID-19 prevention behavior in Bogor (NIHRD). The respondents in the study were validated by PCR swabs based on reports from the COVID-19 task force in Bogor. Samples were gathered from 148 suitable respondents for analysis. COVID-19 severity, supportive examination results (blood tests, radiography, and ECG), signs and symptoms, and demographic factors were all assessed. In the statistical study, simple and multivariate logistic regressions were used. Results: We found that 50.0% of respondents experienced severe symptoms as a result of COVID-19 exposure; symptomatic respondents 78.4%, blood group O 56.10%, age group 8-59 years 71.0%; male 56.1%; impaired blood glucose profile 18.3%, impaired erythrocyte sedimentation rate profile 14.9%, impaired leukocyte profile 64.9%, impaired lymphocyte profile 54.8%, impaired platelet profile 16.4%, impaired AST (ASPARTATE AMINOTRANSFERASE) profile 16.2%, impaired creatinine profile 9.5%, 67.6% of X-ray with GGO/infiltrates. Several risk factors were associated with the severity of COVID-19, including symptom factors (OR 12.59, p-value 0.002, 95% CI=1.46-55.20). ECG examination factor (OR 8.31, p-value 0.002, 95% CI=3.51-107.88) was also associated with severity. Conclusion: Therefore, to avoid the severity of COVID-19, clinical characteristics must be assessed as soon as feasible.